Advanced Biomed Inc. is facing potential delisting from the Nasdaq Capital Market after failing to meet the minimum $1.00 per share bid price requirement, as mandated by Nasdaq Listing Rule 5550(a)(2). The company did not regain compliance by the January 14, 2026 deadline and subsequently received notice that its securities would be suspended and delisted unless an appeal was filed. Advanced Biomed appealed the decision, which temporarily stays the delisting process while a hearings panel reviews the case. The company plans to present a compliance strategy, including a reverse stock split, but there is no assurance the panel will approve continued listing or that compliance will be achieved within any granted timeframe.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Advanced Biomed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-006281), on January 21, 2026, and is solely responsible for the information contained therein.